Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.62 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.54 |
| ▸ | TPMT | P51580 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7168025 | 1.00 | RXRA (0.62) | RXRAMRGPRX4NPC1HPGDRAB9A | |
| SCHEMBL11762649 | 0.97 | RXRA (0.61) | RXRAMRGPRX4NPC1HPGDRAB9A | |
| SCHEMBL15673277 | 0.94 | RXRA (0.62) | RXRAMRGPRX4NPC1HPGDRAB9A | |
| SCHEMBL2317454 | 0.91 | RXRA (0.61) | RXRAMRGPRX4NPC1HPGDRAB9A | |
| SCHEMBL9680174 | 0.90 | NPC1 (0.58) | RXRAMRGPRX4NPC1HPGDRAB9A | |
| Hydrochloric Acid SCHEMBL16143333 | 0.90 | RXRA (0.60) | RXRAMRGPRX4NPC1HPGDRAB9A | |
| SCHEMBL30102538 | 0.89 | HPGD (0.66) | RXRAMRGPRX4NPC1HPGDRAB9A | |
| SCHEMBL28903575 | 0.89 | HPGD (0.66) | RXRAMRGPRX4NPC1HPGDRAB9A | |
| SCHEMBL18397139 | 0.88 | RXRA (0.59) | RXRAMRGPRX4NPC1HPGDRAB9A | |
| SCHEMBL1766201 | 0.87 | RXRA (0.55) | RXRAMRGPRX4NPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | disclosed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | disclosed |
| CN-115417766-B | Synthesis method of 3-hydroxy-4, 5-dimethoxy benzoic acid tert-butyl ester | 天津药明康德新药开发有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-116535365-A | Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | disclosed |
| EP-4132933-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-02-15 | — | — | EP | disclosed |
| CN-115417766-A | Synthesis method of 3-hydroxy-4, 5-dimethoxy benzoic acid tert-butyl ester | 天津药明康德新药开发有限公司 | 2022-12-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | RXRA 1817/4885MRGPRX4 776/4885NPC1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.